The molecular biology of HIV latency: Breaking and restoring the Tat-dependent transcriptional circuit

Current Opinion in HIV and AIDS

Volumn 6, Issue 1, 2011, Pages 4-11

  Karn, Jonathan ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV chromatin; HIV elongation; HIV initiation; HIV Tat; P TEFb

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; TRANSACTIVATOR PROTEIN;

ARTICLE; CHROMATIN ASSEMBLY AND DISASSEMBLY; EPIGENETICS; FEEDBACK SYSTEM; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN IMMUNODEFICIENCY VIRUS; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION INITIATION; VIRUS CELL INTERACTION; VIRUS LATENCY; DRUG ANTAGONISM; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW;

HIV; HUMANS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTION, GENETIC; VIRUS LATENCY;

EID: 79954441735     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328340ffbb     Document Type: Article

References (86)

1. Chun TW, Davey RT Jr, Engel D, et al. Re-emergence of HIV after stopping therapy. Nature 1999; 401:874-875. (Pubitemid 129516777)
2. Davey RT Jr, Bhat N, Yoder C, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A 1999; 96:15109-15114. (Pubitemid 30019773)
3. Shen A, Zink MC, Mankowski JL, et al. Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. J Virol 2003; 77:4938-4949. (Pubitemid 36402842)
4. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-1300. (Pubitemid 27495742)
5. Brennan TP, Woods JO, Sedaghat AR, et al. Analysis of HIV-1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol 2009; 83:8470-8481.
6. Joos B, Fischer M, Kuster H, et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A 2008; 105:16725-16730.
7. Jones K, Kadonaga J, Luciw P, Tjian R. Activation of the AIDS retrovirus promoter by the cellular transcription factor, Sp1. Science 1986; 232:755-759. (Pubitemid 16078720)
8. Olsen HS, Rosen CA. Contribution of the TATA motif to Tat-mediated transcriptional activation of the human immunodeficiency virus gene expression. J Virol 1992; 66:5594-5597.
9. Rittner K, Churcher MJ, Gait MJ, Karn J. The human immunodeficiency virus long terminal repeat includes a specialised initiator element which is required for Tat-responsive transcription. J Mol Biol 1995; 248:562-580.
10. Ross EK, Buckler-White AJ, Rabson AB, et al. Contribution of NF-κB and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: distinct patterns of viral growth are determined by T-cell types. J Virol 1991; 65:4350-4358.
11. Nabel G, Baltimore DA. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 1987; 326:711-713. (Pubitemid 17059793)
12. Perkins ND, Edwards NL, Duckett CS, et al. A cooperative interaction between NF-κB and Sp1 is required for HIV-1 enhancer activation. EMBO J 1993; 12:3551-3558. (Pubitemid 23256442)
13. Chen BK, Feinberg MB, Baltimore D. The κB sites in the human immunodeficiency virus type 1 long terminal repeat enhance virus replication yet are not absolutely required for viral growth. J Virol 1997; 71:5495-5504. (Pubitemid 27258228)
14. Wei P, Garber ME, Fang S-M, et al. A novel cdk9-associated c-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop specific binding to TAR RNA. Cell 1998; 92:451-462. (Pubitemid 28101109)
15. Fujinaga K, Irwin D, Huang Y, et al. Dynamics of human immunodeficiency virus transcription: P-TEFb phosphorylates RD and dissociates negative effectors from the transactivation response element. Mol Cell Biol 2004; 24:787-795. (Pubitemid 38057929)
16. Kim YK, Bourgeois CF, Isel C, et al. Phosphorylation of the RNA polymerase II carboxyl-terminal domain by CDK9 is directly responsible for human immunodeficiency virus type 1 Tat-activated transcriptional elongation. Mol Cell Biol 2002; 22:4622-4637. (Pubitemid 34620399)
17. Bourgeois CF, Kim YK, Churcher MJ, et al. Spt5 cooperates with Tat by preventing premature RNA release at terminator sequences. Mol Cell Biol 2002; 22:1079-1093. (Pubitemid 34094845)
18. Ivanov D, Kwak YT, Guo J, Gaynor RB. Domains in the SPT5 protein that modulate its transcriptional regulatory properties. Mol Cell Biol 2000; 20:2970-2983. (Pubitemid 30215010)
19. Tahirov TH, Babayeva ND, Varzavand K, et al. Crystal structure of HIV-1 Tat complexed with human P-TEFb. Nature 2010; 465:747-751.
20. Weinberger LS, Burnett JC, Toettcher JE, et al. Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell 2005; 122:169-182. (Pubitemid 41032982)
21. Weinberger LS, Dar RD, Simpson ML. Transient-mediated fate determination in a transcriptional circuit of HIV. Nat Genet 2008; 40:466-470. (Pubitemid 351450884)
22. Burnett JC, Miller-Jensen K, Shah PS, et al. Control of stochastic gene expression by host factors at the HIV promoter. PLoS Pathog 2009; 5:e1000260.
23. Pearson R, Kim YK, Hokello J, et al. Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency. J Virol 2008; 82:12291-12303.
24. + T cells are enriched for HIV-1 Tat variants with impaired transactivation activity. Virology 2009; 387:98-108.
25. Lewinski MK, Yamashita M, Emerman M, et al. Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathog 2006; 2:e60.
26. Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 2003; 22:1868-1877. (Pubitemid 36460143)
27. Lewinski MK, Bisgrove D, Shinn P, et al. Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. J Virol 2005; 79:6610-6619. (Pubitemid 40677292)
28. Han Y, Lassen K, Monie D, et al. Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol 2004; 78:6122-6133. (Pubitemid 38715910)
29. Vatakis DN, Kim S, Kim N, et al. Human immunodeficiency virus integration efficiency and site selection in quiescent CD4+ T cells. J Virol 2009; 83:6222-6233.
30. Verdin E, Paras PJ, Van Lint C. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 1993; 12:3249-3259. (Pubitemid 23232756)
31. Keedy KS, Archin NM, Gates AT, et al. A limited group of class I histone deacetylases act to repress human immunodeficiency virus type-1 expression. J Virol 2009; 83:4749-4756.
32. Williams SA, Chen LF, Kwon H, et al. NF-κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 2006; 25:139-149. (Pubitemid 43077303)
33. Tyagi M, Karn J. CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J 2007; 26:4985-4995. (Pubitemid 350261291)
34. Tyagi M, Pearson RJ, Karn J. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J Virol 2010; 84:6425-6437.
35. Du Chene I, Basyuk E, Lin YL, et al. Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and postintegration latency. EMBO J 2007; 26:424-435. (Pubitemid 46160943)
36. Marban C, Suzanne S, Dequiedt F, et al. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J 2007; 26:412-423. (Pubitemid 46160942)
37. Archin NM, Keedy KS, Espeseth A, et al. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS 2009; 23:1799-1806.
38. Imai K, Togami H, Okamoto T. Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. J Biol Chem 2010; 285:16538-16545.
39. Blazkova J, Trejbalova K, Gondois-Rey F, et al. CpG methylation controls reactivation of HIV from latency. PLoS Pathog 2009; 5:e1000554.
40. Kauder SE, Bosque A, Lindqvist A, et al. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 2009; 5:e1000495.
41. Lenasi T, Contreras X, Peterlin BM. Transcriptional interference antagonizes proviral gene expression to promote HIV latency. Cell Host Microbe 2008; 4:123-133.
42. Han Y, Lin YB, An W, et al. Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe 2008; 4:134-146.
43. Duverger A, Jones J, May J, et al. Determinants of the establishment of human immunodeficiency virus type 1 latency. J Virol 2009; 83:3078-3093.
44. Brooks DG, Kitchen SG, Kitchen CM, et al. Generation of HIV latency during thymopoiesis. Nat Med 2001; 7:459-464. (Pubitemid 32298549)
45. Brenchley JM, Hill BJ, Ambrozak DR, et al. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol 2004; 78:1160-1168. (Pubitemid 38095826)
46. Bosque A, Planelles V. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood 2008; 113:58-65.
47. Yang HC, Xing S, Shan L, et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest 2009; 119:3473-3486.
48. Burke B, Brown HJ, Marsden MD, et al. Primary cell model for activation-inducible human immunodeficiency virus. J Virol 2007; 81:7424-7434. (Pubitemid 47047831)
49. Adams M, Sharmeen L, Kimpton J, et al. Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts. Proc Natl Acad Sci U S A 1994; 91:3862-3866. (Pubitemid 24139532)
50. Nguyen VT, Kiss T, Michels AA, Bensaude O. 7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes. Nature 2001; 414:322-325. (Pubitemid 33097810)
51. Yang Z, Zhu Q, Luo K, Zhou Q. The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. Nature 2001; 414:317-322. (Pubitemid 33097809)
52. Yik JH, Chen R, Nishimura R, et al. Inhibition of P-TEFb (CDK9/Cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA. Mol Cell 2003; 12:971-982. (Pubitemid 37352789)
53. Michels AA, Fraldi A, Li Q, et al. Binding of the 7SK snRNA turns the HEXIM1 protein into a P-TEFb (CDK9/cyclin T) inhibitor. EMBO J 2004; 23:2608-2619. (Pubitemid 38988232)
54. Chen R, Liu M, Li H, et al. PP2B and PP1alpha cooperatively disrupt 7SK snRNP to release P-TEFb for transcription in response to Ca2+ signaling. Genes Dev 2008; 22:1356-1368. (Pubitemid 351717526)
55. Cho S, Schroeder S, Kaehlcke K, et al. Acetylation of cyclin T1 regulates the equilibrium between active and inactive P-TEFb in cells. EMBO J 2009; 28:1407-1417.
56. Zhang Z, Klatt A, Gilmour DS, Henderson AJ. Negative elongation factor NELF represses human immunodeficiency virus transcription by pausing the RNA polymerase II complex. J Biol Chem 2007; 282:16981-16988. (Pubitemid 47093194)
57. Ping Y-H, Rana TM. DSIF and NELF interact with RNA polymerase II elongation complex and HIV-1 Tat stimulates P-TEFb-mediated phosphorylation of RNA polymerase II and DSIF during transcription elongation. J Biol Chem 2001; 276:12951-12958.
58. Kinoshita S, Su L, Amano M, et al. The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. Immunity 1997; 6:235-244. (Pubitemid 27148590)
59. Stroud JC, Oltman A, Han A, et al. Structural basis of HIV-1 activation by NF-κB - a higher order complex of p50:RelA bound to the HIV-1 LTR. J Mol Biol 2009; 393:98-112.
60. Giffin MJ, Stroud JC, Bates DL, et al. Structure of NFAT1 bound as a dimer to the HIV-1 LTR κB element. Nat Struct Biol 2003; 10:800-806. (Pubitemid 37187650)
61. Lusic M, Marcello A, Cereseto A, Giacca M. Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter. EMBO J 2003; 22:6550-6561. (Pubitemid 38009602)
62. Benkirane M, Chun RF, Xiao H, et al. Activation of integrated provirus requires histone acetyltransferase: p300 and p/CAF are coactivators for HIV-1 Tat. J Biol Chem 1998; 273:24898-24905. (Pubitemid 28454997)
63. Hottiger MO, Nabel GJ. Interaction of human immunodeficiency virus type 1 Tat with the transcriptional coactivators p300 and CREB binding protein. J Virol 1998; 72:8252-8256. (Pubitemid 28421822)
64. Marzio G, Tyagi M, Gutierrez MI, Giacca M. HIV-1 Tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. Proc Natl Acad Sci U S A 1998; 95:13519-13524. (Pubitemid 28523004)
65. Mahmoudi T, Parra M, Vries RG, et al. The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter. J Biol Chem 2006; 281:19960-19968. (Pubitemid 44065769)
66. Chen LF, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-κB action regulated by reversible acetylation. Science 2001; 293:1653-1657. (Pubitemid 32807844)
67. Lu T, Jackson MW, Wang B, et al. Regulation of NF-κB by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proc Natl Acad Sci U S A 2010; 107:46-51.
68. García-Rodríguez C, Rao A. Nuclear factor of activated T cells (NFAT)-dependent transactivation regulated by the coactivators p300/CREB-binding protein (CBP). J Exp Med 1998; 187:2031-2036. (Pubitemid 28285572)
69. Robichaud GA, Barbeau B, Fortin J-F, et al. Nuclear factor of activated T cells is a driving force for preferential productive HIV-1 infection of CD45ROexpressing CD4+ T cells. J Biol Chem 2002; 277:23733-23741. (Pubitemid 34952214)
70. Kinoshita S, Chen BK, Kaneshima H, Nolan GP. Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells. Cell 1998; 95:595-604. (Pubitemid 28544121)
71. Brooks DG, Arlen PA, Gao L, et al. Identification of T cell-signaling pathways that stimulate latent HIV in primary cells. Proc Natl Acad Sci U S A 2003; 100:12955-12960. (Pubitemid 37340007)
72. Thibault S, Imbeault M, Tardif MR, Tremblay MJ. TLR5 stimulation is sufficient to trigger reactivation of latent HIV-1 provirus in T lymphoid cells and activate virus gene expression in central memory CD4+ T cells. Virology 2009; 389:20-25.
73. Wolschendorf F, Duverger A, Jones J, et al. Hit-and-Run Stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction. J Virol 2010; 84:8712-8720.
74. Williams SA, Kwon H, Chen LF, Greene WC. Sustained induction of NF-κB is required for efficient expression of latent human immunodeficiency virus type 1. J Virol 2007; 81:6043-6056. (Pubitemid 46847040)
75. He N, Liu M, Hsu J, et al. HIV-1 Tat and host AFF4 recruit two transcription elongation factors into a bifunctional complex for coordinated activation of HIV-1 transcription. Mol Cell 2010; 38:428-438.
76. Sobhian B, Laguette N, Yatim A, et al. HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP. Mol Cell 2010; 38:439-451.
77. Chun T-W, Engel D, Berrey MM, et al. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A 1998; 95:8869-8873. (Pubitemid 28350581)
78. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9:727-728. (Pubitemid 36749221)
79. Ramratnam B, Mittler JE, Zhang L, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy. Nat Med 2000; 6:82-85. (Pubitemid 30048531)
80. Chun T-W, Nickle DC, Justement JS, et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 2005; 115:3250-3255. (Pubitemid 41567589)
81. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15:893-900.
82. Dinoso JB, Kim SY, Wiegand AM, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 2009; 106:9403-9408.
83. Richman DD, Margolis DM, Delaney M, et al. The challenge of finding a cure for HIV infection. Science 2009; 323:1304-1307.
84. Trono D, Van Lint C, Rouzioux C, et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010; 329:174-180.
85. Savarino A, Mai A, Norelli S, et al. "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology 2009; 6:52.
86. Bowman MC, Archin NM, Margolis DM. Pharmaceutical approaches to eradication of persistent HIV infection. Expert Rev Mol Med 2009; 11:e6.